Work

Cardiometabolic risk factors efficacy of semaglutide in the STEP program

Year: 2022
Type: article
Abstract: , improvements in lipid profile, and stabilization of SBP. Overall, across the STEP trials, treatment with semaglutide 2.4 mg versus placebo improved cardiometabolic risk factors associated with obesity, illustrating an effective treatment option for people with overweight (and associated comorbidities) or obesity.
Language: English
Field: Medicine
Open Access status: hybrid
Funder: Novo Nordisk
OpenAlex ID: W4317869445
FWCI: 1.988
Cites: 39
Cited by: 21
Related to: 10